In this phase II clinical trial, we evaluate the efficacy and feasibility of conditioning regimen of fludarabine 150mg/m2, busulfan 9.6mg/kg, melphalan 100mg/m2 and etoposide 800mg/m2 in patients with lymphoid malignancies.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
23
Fludarabine 150mg/m2, busulfan 6.4mg/kg, melphalan 100mg/m2 and etoposide 600mg/m2
Blood & Marrow Transplantation Center, RuiJin Hospital
Shanghai, China
RECRUITINGdisease-free survival
event defined as disease progression, relapse or death of any causes
Time frame: 1 year after allo-HSCT
Overall survival
event defined as death of any causes
Time frame: 1 year after allo-HSCT
Non relapse morality
event defined as death of any causes except for disease progression or relapse
Time frame: 1 year after allo-HSCT
Relapse
event defined as disease progression or relapse
Time frame: 1 year after allo-HSCT
GVHD-free or relapse-free survival
event defined as disease progression or relapse, death of any cause, grade III-IV aGVHD or moderate to severe cGVHD
Time frame: 1 year after allo-HSCT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.